Fabry disease: Multidisciplinary evaluation after 10 years of treatment with agalsidase beta

JIMD Reports

Volumn 16, Issue , 2014, Pages 7-14

  Juan, Politei ^a   Hernan, Amartino ^b   Beatriz, Schenone Andrea ^a   Gustavo, Cabrera ^c   Antonio, Michref ^d   Eduardo, Tanus ^d   Raul, Dominguez ^d   Margarita, Larralde ^e   Mariana, Blanco ^a   Daniela, Gaggioli ^a   Marina, Szlago ^a  

^a Laboratorio de Neuroquímica Dr NA Chamoles   (Argentina)

^b Austral Hospital   (Argentina)

^c Del Viso Medical Group   (Argentina)

^d Sirio Libanes Hospital   (Argentina)

^e HOSPITAL ALEMÁN   (Argentina)

Author keywords

Brain magnetic resonance imaging; Enzyme replacement therapy; Fabry disease; Left ventricular hypertrophy; Neuropathic pain

Indexed keywords

EID: 84930001296     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2014_310     Document Type: Chapter

References (26)

1. Banikazemi M, Bultas J, Waldek S, Wilcox WR et al (2007) Agalsidase beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77–86
2. Cole AL, Lee PJ, Hughes DA, Deegan PB, Waldek S, Lachmann RH (2007) Depression in adults with Fabry disease: a common and under-diagnosed problem. J Inherit Metab Dis 30:943–951
3. Eng CM, Gurron N, Wilcox WR et al (2001) Safety and efficacy of recombinant human ∝-galactosidase A-replacement therapy in Fabry’s disease. N Engl J Med 345:9–16
4. Fellgiebel A, Müuller MJ, Mazanek M, Baron K, Beck M, Stoeter P (2005) White matter lesion severity in male and female patients with Fabry disease. Neurology 65(4):600–602
5. Fellgiebel A, Keller I, Martus P et al (2011) Basilar artery diameter is a potential screening tool for Fabry disease in young stroke patients. Cerebrovasc Dis 31:294–299
6. Furujo M, Kubo T, Kobayashi M, Ohashi T (2013) Enzyme replacement therapy in two Japanese siblings with Fabry disease, and its effectiveness onangiokeratoma and neuropathic pain. Mol Genet Metab 110(3):405–410
7. Germain D (2010) Fabry disease. Orphanet J Rare Dis 5:1–49
8. Germain DP, Waldek S, Banikazemi M et al (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18:1547–1557
9. Germain DP, Weidemann F, Abiose A et al (2013) Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry. Genet Med 15:958–965
10. Gold KF, Pastores GM, Botteman MF et al (2002) Quality of life of patients with Fabry disease. Qual Life Res 11:317–327
11. Hilz MJ, Brys M, Marthol H, Stemper B, Düutsch M (2004) Enzyme replacement therapy improves function of C, Adelta, and Abeta nerve fibers in Fabryneuropathy. Neurology 62:1066–1072
12. Lang RM, Bierig M, Devereux RB et al (2005) Chamber Quantification Writing Group; American Society of Echocardiography’s Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification. J Am Soc Echocardiogr 18:1440–1463
13. Lukas J, Giese AK, Markoff A et al (2013) Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in Fabry disease. PLoS Genet 9(8): e1003632
14. Miners AH, Holmes A, Sherr L, Jenkinson G, MacDermot K (2002) Assessment of health-related quality of life in males with Anderson Fabry disease before therapeutic intervention. Qual Life Res 11:127–133
15. Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE (2013) Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis 47:1–9
16. Schiffmann R, Kopp JB, Austin HA 3rd et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743–2749
17. Sergi B, Conti G, Paludetti G (2010) Interdisciplinary study group on Fabry disease. Inner ear involvement in Anderson-Fabry disease: long-term follow-up during enzyme replacement therapy. Acta Otorhinolaryngol Ital 30:87–93
18. Spada M, Pagliardini S, Yasuda M et al (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79:31–40
19. Street NJ, Yi MS, Bailey LA, Hopkin R (2006) Comparison of health-related quality of life between heterozygous women with Fabry disease, a healthy control population, and patients with other chronic disease. Genet Med 8:346–353
20. Tøndel C, Bostad L, Larsen KK et al (2013) Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 24:137–148
21. Wang RY, Lelis A, Mirocha J, Wilcox WR (2007) Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 9:34–45
22. Ware JE, Snow KK, Kosinski M et al (1993) SF-36 Health Survey manual and interpretation guide. New England Medical Center, The Health Institute, Boston
23. Watt T, Burlina AP, Cazzorla C et al (2010) Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry. Genet Med 12:703–712
24. Weidemann F, Niemann M, Breunig F et al (2009) Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 119:524–529
25. Weidemann F, Sanchez-Niño MD, Politei J et al (2013a) Fibrosis: a key feature of Fabry disease with potential therapeutic implications. Orphanet J Rare Dis 8:1–12
26. Weidemann F, Niemann M, Stüörk S et al (2013b) Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med 274:331–341